{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:39:55Z","timestamp":1781534395259,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41574-021-00537-7","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T17:04:22Z","timestamp":1626455062000},"page":"519-520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolically healthy obesity: time for a change of heart?"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6128-0822","authenticated-orcid":false,"given":"Daniel J.","family":"Cuthbertson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P. H.","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"537_CR1","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1001\/archinte.168.15.1609","volume":"168","author":"N Stefan","year":"2008","unstructured":"Stefan, N. et al. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 168, 1609\u20131616 (2008).","journal-title":"Arch. Intern. Med."},{"key":"537_CR2","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1172\/JCI129186","volume":"129","author":"GI Smith","year":"2019","unstructured":"Smith, G. I., Mittendorfer, B. & Klein, S. Metabolically healthy obesity: facts and fantasies. J. Clin. Invest. 129, 3978\u20133989 (2019).","journal-title":"J. Clin. Invest."},{"key":"537_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8505","volume":"4","author":"A Zembic","year":"2021","unstructured":"Zembic, A., Eckel, N., Stefan, N., Baudry, J. & Schulze, M. B. An empirically derived definition of metabolically healthy obesity based on risk of cardiovascular and total mortality. JAMA Netw. Open 4, e218505 (2021).","journal-title":"JAMA Netw. Open"},{"key":"537_CR4","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jacc.2017.07.763","volume":"70","author":"R Caleyachetty","year":"2017","unstructured":"Caleyachetty, R. et al. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J. Am. Coll. Cardiol. 70, 1429\u20131437 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"537_CR5","doi-asserted-by":"publisher","first-page":"758","DOI":"10.7326\/0003-4819-159-11-201312030-00008","volume":"159","author":"CK Kramer","year":"2013","unstructured":"Kramer, C. K., Zinman, B. & Retnakaran, R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann. Intern. Med. 159, 758\u2013769 (2013).","journal-title":"Ann. Intern. Med."},{"key":"537_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/ijo.2015.151","volume":"40","author":"R Dobson","year":"2016","unstructured":"Dobson, R. et al. Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity. Int. J. Obes. 40, 153\u2013161 (2016).","journal-title":"Int. J. Obes."},{"key":"537_CR7","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2227","author":"Y Commodore-Mensah","year":"2021","unstructured":"Commodore-Mensah, Y. et al. High burden of subclinical and cardiovascular disease risk in adults with metabolically healthy obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care https:\/\/doi.org\/10.2337\/dc20-2227 (2021).","journal-title":"Diabetes Care"},{"key":"537_CR8","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jacc.2013.11.035","volume":"63","author":"B Morkedal","year":"2013","unstructured":"Morkedal, B., Vatten, L. J., Romundstad, P. R., Laugsand, L. E. & Janszky, I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals. The HUNT Study, Norway. J. Am. Coll. Cardiol. 63, 1071\u20131078 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"537_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05484-6","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z. et al. Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants. Diabetologia https:\/\/doi.org\/10.1007\/s00125-021-05484-6 (2021).","journal-title":"Diabetologia"},{"key":"537_CR10","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.jacc.2018.02.055","volume":"71","author":"M Mongraw-Chaffin","year":"2018","unstructured":"Mongraw-Chaffin, M. et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J. Am. Coll. Cardiol. 71, 1857\u20131865 (2018).","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-021-00537-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-021-00537-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-021-00537-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:05:43Z","timestamp":1628600743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-021-00537-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1038\/s41574-021-00537-7","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"16 July 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.J.C. has received funding for investigator-initiated studies from AstraZeneca, Novo Nordisk, Pfizer, Ipsen and Boehringer Ingelheim and educational grants from Janssen Pharmaceuticals, Lilly and Sanofi. J.P.H.W. has acted as a consultant, received institutional grants, and given lectures on behalf of pharmaceutical companies developing or marketing medicines used for the treatment of diabetes and obesity, specifically Astellas, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Mundipharma, Napp, Novo Nordisk, Orexigen, Rhythm Pharmaceuticals, Sanofi and Takeda, and Wilmington Healthcare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}